Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

3(60.0%)

Phase 2

2(40.0%)

5Total

Phase 1(3)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT00494234Phase 2Completed

Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer

Role: collaborator

NCT00494442Phase 2Completed

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer

Role: collaborator

NCT00516438Phase 1Completed

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan

Role: collaborator

NCT00516802Phase 1Completed

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine

Role: collaborator

NCT00633269Phase 1Completed

Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours

Role: collaborator

All 5 trials loaded